
|Articles|January 1, 2005
Trial to study potential MMD treatment
Waltham, MA-OXiGENE Inc. is launching a phase II clinical trial of its lead compound, Combretastatin A4 Prodrug (CA4P), in patients with myopic macular degeneration (MMD) under an investigational new drug application (NDA) submitted to the FDA.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
UPDATE: STAAR postpones Alcon merger vote, Broadwood calls for removal of board members
2
Topcon Healthcare seeks to advance company through acquisition and new investment
3
VR and imaging advancements showcased at AAO 2025
4
Regeneron receives another CRL for its Eyelea 8 mg
5

















































.png)


